Destiny Pharma PLC (AIM:DEST) Neil Clark talks to Proactive London about their partner in China, Hong Kong listed China Medical System Holdings (HKG:0867) Ltd (CMS) launching a new programme aimed at delivering a new product using Destiny’s XF-73.
Their aim differs to Destiny as Neil explains, targeting the prevention and treatment of superficial skin infections caused by bacteria. The firm is also an investor with an over 10% stake.
They'll be running their own programme, but both parties will benefit by sharing the data and developments made by both parties. CMS will lead, manage and fund the programme, with Destiny contributing scientific advice as required through a steering committee to the expert dermatology team at CMS.
